ObjectiveTo evaluate the clinical efficacy and safety of Tengshen Granules in the treatment of grade 1 hypertension with the syndrome of severe liver heat and hyperactive Yang combined with mild kidney Yin deficiency. MethodsA total of 120 patients with grade 1 hypertension presenting with severe liver heat and hyperactive Yang combined with mild kidney Yin deficiency were enrolled in a randomized， double-blind， placebo-controlled， parallel-group clinical trial. Patients were randomly assigned to the observation group （Tengshen granules） and the control group （placebo）， with 60 cases in each group. On the basis of lifestyle intervention， treatment was administered for 8 weeks followed by a 2-month follow-up. During the study period， traditional Chinese medicine （TCM） syndrome scores， blood pressure， antihypertensive efficacy， blood pressure control rate， and other indicators were recorded and analyzed， and safety was evaluated. ResultsA total of 114 patients completed the trial， including 57 in the control group and 57 in the observation group. Compared with baseline， TCM syndrome scores， systolic blood pressure， and diastolic blood pressure in the observation group were significantly reduced after treatment （P<0.01）. Compared with the control group after treatment， systolic blood pressure in the observation group was lower from week 4 of medication （P<0.05）， and this difference persisted until 2 months after drug discontinuation. For diastolic blood pressure， the observation group was superior to the control group at week 8 （P<0.01）， with no statistically significant differences at other time points. Regarding syndrome improvement， the TCM syndrome scores for severe liver heat and hyperactive Yang combined with mild kidney Yin deficiency showed significant improvement at weeks 6 and 8 of treatment， with the observation group superior to the control group （P<0.05）. During the 1-month follow-up after drug discontinuation， the syndrome scores in the observation group remained lower than those in the control group （P<0.01）. The total effective rate of antihypertensive efficacy in the observation group was higher than that in the control group （χ²=11.389， P<0.05）. In addition， the level of urinary microalbumin in the observation group was lower after treatment than before treatment （P<0.05）. ConclusionTengshen granules demonstrate significant clinical efficacy and good safety in the treatment of grade 1 hypertension with severe liver heat and hyperactive Yang combined with mild kidney Yin deficiency. They can effectively reduce blood pressure and improve related TCM syndrome manifestations.

ObjectiveTo evaluate the clinical efficacy and safety of Tengshen Granules in the treatment of grade 1 hypertension with the syndrome of severe liver heat and hyperactive Yang combined with mild kidney Yin deficiency. MethodsA total of 120 patients with grade 1 hypertension presenting with severe liver heat and hyperactive Yang combined with mild kidney Yin deficiency were enrolled in a randomized， double-blind， placebo-controlled， parallel-group clinical trial. Patients were randomly assigned to the observation group （Tengshen granules） and the control group （placebo）， with 60 cases in each group. On the basis of lifestyle intervention， treatment was administered for 8 weeks followed by a 2-month follow-up. During the study period， traditional Chinese medicine （TCM） syndrome scores， blood pressure， antihypertensive efficacy， blood pressure control rate， and other indicators were recorded and analyzed， and safety was evaluated. ResultsA total of 114 patients completed the trial， including 57 in the control group and 57 in the observation group. Compared with baseline， TCM syndrome scores， systolic blood pressure， and diastolic blood pressure in the observation group were significantly reduced after treatment （P<0.01）. Compared with the control group after treatment， systolic blood pressure in the observation group was lower from week 4 of medication （P<0.05）， and this difference persisted until 2 months after drug discontinuation. For diastolic blood pressure， the observation group was superior to the control group at week 8 （P<0.01）， with no statistically significant differences at other time points. Regarding syndrome improvement， the TCM syndrome scores for severe liver heat and hyperactive Yang combined with mild kidney Yin deficiency showed significant improvement at weeks 6 and 8 of treatment， with the observation group superior to the control group （P<0.05）. During the 1-month follow-up after drug discontinuation， the syndrome scores in the observation group remained lower than those in the control group （P<0.01）. The total effective rate of antihypertensive efficacy in the observation group was higher than that in the control group （χ²=11.389， P<0.05）. In addition， the level of urinary microalbumin in the observation group was lower after treatment than before treatment （P<0.05）. ConclusionTengshen granules demonstrate significant clinical efficacy and good safety in the treatment of grade 1 hypertension with severe liver heat and hyperactive Yang combined with mild kidney Yin deficiency. They can effectively reduce blood pressure and improve related TCM syndrome manifestations.

Objective To provide a reference for the clinical individualized medication of hypertension,the antihypertensive efficacy of Gouteng Xuanshen prescription in the treatment of hypertension was verified,and its improvement on the discomfort symptoms of patients was explored.Methods This study adopted a retrospective cohort study design.The data were derived from the electronic medical records of 6770 hypertensive patients in the Affiliated Hospital of Shandong University of Traditional Chinese Medicine from January 1,2013 to January 1,2023.The exposure factor was the treatment of Uncaria rhynchophylla,Scrophularia ningpoensis,and Radish Seed.After the propensity score was used to deal with the confounding factors,the changes in blood pressure of the patients after treatment were observed.At the same time,in order to analyze the improvement of patients'symptoms,the Apriori algorithm to mine the core symptoms of patients was explored,and the patient symptom network was constructed.The BGLL algorithm was used to divide the symptoms into communities to form a symptom map.Finally,survival analysis and Cox regression were used to find the sensitive symptom community of Gouteng Xuanshen prescription,and the related factors were analyzed.Results 468 people were included in the exposure group and the control group.After treatment,more patients in the exposure group reached the target blood pressure(P<0.01),and the effect was better in lowering systolic blood pressure(P<0.05),and no obvious abnormalities in safety indicators were found.In terms of symptom improvement,the 134 symptoms recorded in the medical records were divided into 6 groups.As the medication time increased,the patient's head discomfort was easier to relieve.The effect was best at 8 weeks of treatment,and it was more sensitive to patients with extremely high cardiovascular risk or grade 3 hypertension.Conclusion This study verified the clinical efficacy of the Gouteng Xuanshen prescription in the treatment of hypertension through electronic medical record data,which preliminarily revealed the potential role and law of the Gouteng Xuanshen prescription in the treatment of hypertension.

Objective To provide a reference for the clinical individualized medication of hypertension,the antihypertensive efficacy of Gouteng Xuanshen prescription in the treatment of hypertension was verified,and its improvement on the discomfort symptoms of patients was explored.Methods This study adopted a retrospective cohort study design.The data were derived from the electronic medical records of 6770 hypertensive patients in the Affiliated Hospital of Shandong University of Traditional Chinese Medicine from January 1,2013 to January 1,2023.The exposure factor was the treatment of Uncaria rhynchophylla,Scrophularia ningpoensis,and Radish Seed.After the propensity score was used to deal with the confounding factors,the changes in blood pressure of the patients after treatment were observed.At the same time,in order to analyze the improvement of patients'symptoms,the Apriori algorithm to mine the core symptoms of patients was explored,and the patient symptom network was constructed.The BGLL algorithm was used to divide the symptoms into communities to form a symptom map.Finally,survival analysis and Cox regression were used to find the sensitive symptom community of Gouteng Xuanshen prescription,and the related factors were analyzed.Results 468 people were included in the exposure group and the control group.After treatment,more patients in the exposure group reached the target blood pressure(P<0.01),and the effect was better in lowering systolic blood pressure(P<0.05),and no obvious abnormalities in safety indicators were found.In terms of symptom improvement,the 134 symptoms recorded in the medical records were divided into 6 groups.As the medication time increased,the patient's head discomfort was easier to relieve.The effect was best at 8 weeks of treatment,and it was more sensitive to patients with extremely high cardiovascular risk or grade 3 hypertension.Conclusion This study verified the clinical efficacy of the Gouteng Xuanshen prescription in the treatment of hypertension through electronic medical record data,which preliminarily revealed the potential role and law of the Gouteng Xuanshen prescription in the treatment of hypertension.

The human immune system plays a key role in maintaining tissue homeostasis and disease progression. The development of biomaterials that can regulate the innate immune system and adapt to the immune system has great application prospects in the field of tissue engineering. This paper discusses how to design the surface interface topographies or the physicochemical properties of biomaterials, to regulate the fate of macrophages, such as activation, polarization, adhesion, migration, proliferation, and secretion. At the same time, the application of these biomaterials with immunoregulation function in the field of wound healing is discussed. In addition, this paper also put forward the limitations of biomaterials in immunoregulation applications and prospected the future development directions.